Venus Remedies Limited (BOM:526953)
1,780.10
-6.70 (-0.37%)
At close: Aug 17, 2026
Venus Remedies Revenue
Venus Remedies had revenue of 1.79B INR in the quarter ending June 30, 2026, with 35.60% growth. This brings the company's revenue in the last twelve months to 8.11B, up 20.87% year-over-year. In the fiscal year ending March 31, 2026, Venus Remedies had annual revenue of 7.70B with 17.88% growth.
Revenue (ttm)
8.11B
Revenue Growth
+20.87%
P/S Ratio
2.94
Revenue / Employee
5.51M
Employees
1,472
Market Cap
23.88B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 7.70B | 1.17B | 17.88% |
| Mar 31, 2025 | 6.53B | 514.43M | 8.55% |
| Mar 31, 2024 | 6.01B | 459.40M | 8.27% |
| Mar 31, 2023 | 5.56B | -446.71M | -7.44% |
| Mar 31, 2022 | 6.00B | 520.57M | 9.50% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Unichem Laboratories | 23.17B |
| Hikal | 17.35B |
| Gufic Biosciences | 9.81B |
| TTK Healthcare | 8.88B |
| Fredun Pharmaceuticals | 7.44B |
| Kwality Pharmaceuticals | 5.54B |
| Amrutanjan Health Care | 5.11B |
| Fermenta Biotech | 5.11B |
Venus Remedies News
- 5 weeks ago - Venus Remedies announces special window for re-lodgement of physical share transfers - Business Upturn
- 2 months ago - Venus Remedies urges shareholders to update KYC details via social media - Business Upturn
- 2 months ago - Venus Remedies secures renewal of DSIR in-house R&D recognition - Business Upturn
- 2 months ago - Venus Remedies hits 5% upper circuit at all-time high as FY26 profit more than doubles to ₹102.78 crore - Business Upturn
- 2 months ago - Venus Remedies announces ₹10 per share final dividend with record date set for August 2026 - Business Upturn
- 2 months ago - Venus Remedies schedules AGM for August 2026 and announces dividend - Business Upturn
- 3 months ago - Venus Remedies shares rally 4% after Saudi Arabia approves oncology drug Plerixafor for global marketing authorization - Business Upturn
- 3 months ago - Venus Remedies receives Saudi FDA approval for Plerixafor - Business Upturn